Blackford has entered a commercial partnership with Lucida Medical to integrate Lucida's prostate cancer MRI imaging software (Pi) into its AI platform.
Pi is designed to help healthcare professionals work more quickly by automating laborious steps and increasing accuracy for MRI detection of clinically significant prostate cancer. The software has proven effective in supporting analysis of prostate MRIs in real-world applications across multiple healthcare settings, scanner types, and vendors, Blackford said.
Lucida Medical is a spin-off company out of Cambridge University in England. Blackford’s AI platform provides access to more than 120 AI products designed to drive clinical efficiencies and improve patient outcomes, the company noted.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
